 2020 Q3 Earnings Call Summary

Chemed Corporation reported its third quarter 2020 operating results. Both VITAS and Roto-Rooter have reengineered their operating procedures to safely care for patients and customers during the pandemic. VITAS' hospice segment operations were impacted by the pandemic, but the federal government provided support to relax regulations and allow for pragmatic flexibility in caring for patients. Roto-Rooter services demand began to show weekly improvement beginning in the later part of April and has strengthened unabated throughout the second and third quarters of 2020. Chemed's full year 2020 adjusted EBITDA margin prior to Medicare Cap is estimated to be 21%. Chemed is currently estimating $8.6 million for Medicare Cap billing limitations for calendar year 2020. Roto-Rooter is forecasted to achieve full year 2020 revenue growth of 12.5% to 13%. Chemed's full year 2020 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits for stock options, costs related to litigation and other discrete items, is estimated to be in the range of $18 to $18.15.